polinucleotídeos codificadores de relaxina
a invenção refere-se a terapia de rnam para o tratamento de fibrose e/ou doença cardiovascular, os rnam para utilização na invenção, quando administrados in vivo, codificam a relaxina humana, as suas isoformas, fragmentos funcionais das mesmas, e proteínas de fusão compreendendo relaxina, mrnas da i...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KERRY BENENATO ZHINAN XIA VLADIMIR PRESNYAK BARRY TICHO ATHANASIOS DOUSIS NADEGE BRIANCON-ERIS SEYMOUR DE PICCIOTTO STEPHEN HOGE ELLALAHEWAGE SATHYAJITH KUMARASINGHE IAIN MCFADYEN |
| description | a invenção refere-se a terapia de rnam para o tratamento de fibrose e/ou doença cardiovascular, os rnam para utilização na invenção, quando administrados in vivo, codificam a relaxina humana, as suas isoformas, fragmentos funcionais das mesmas, e proteínas de fusão compreendendo relaxina, mrnas da invenção são preferencialmente encapsulados em nanopartículas de lipídeos (lnps) para efetuar a entrega eficiente a células e/ou tecidos em sujeitos, quando administrado ao mesmo, terapias de rnam do aumento invenção e/ou restaurar níveis insuficientes de expressão e/ou atividade da relaxina em indivíduos, terapias de rnam de a invenção ainda diminuir os níveis de metabolitos tóxicos associados com a atividade da relaxina deficiente em indivíduos.
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BR112018073683A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BR112018073683A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BR112018073683A23</originalsourceid><addsrcrecordid>eNrjZNAuyM_JzCtNzknNLzm8NiU1v1ghOT8lMy0zOTElvyi1WCElVaEoNSexIjMvkYeBNS0xpziVF0pzM6i6uYY4e-imFuTHpxYXJCan5qWWxDsFGRoaGRhaGJgbm1kYOxoZE6sOAEu5LEk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>polinucleotídeos codificadores de relaxina</title><source>esp@cenet</source><creator>KERRY BENENATO ; ZHINAN XIA ; VLADIMIR PRESNYAK ; BARRY TICHO ; ATHANASIOS DOUSIS ; NADEGE BRIANCON-ERIS ; SEYMOUR DE PICCIOTTO ; STEPHEN HOGE ; ELLALAHEWAGE SATHYAJITH KUMARASINGHE ; IAIN MCFADYEN</creator><creatorcontrib>KERRY BENENATO ; ZHINAN XIA ; VLADIMIR PRESNYAK ; BARRY TICHO ; ATHANASIOS DOUSIS ; NADEGE BRIANCON-ERIS ; SEYMOUR DE PICCIOTTO ; STEPHEN HOGE ; ELLALAHEWAGE SATHYAJITH KUMARASINGHE ; IAIN MCFADYEN</creatorcontrib><description>a invenção refere-se a terapia de rnam para o tratamento de fibrose e/ou doença cardiovascular, os rnam para utilização na invenção, quando administrados in vivo, codificam a relaxina humana, as suas isoformas, fragmentos funcionais das mesmas, e proteínas de fusão compreendendo relaxina, mrnas da invenção são preferencialmente encapsulados em nanopartículas de lipídeos (lnps) para efetuar a entrega eficiente a células e/ou tecidos em sujeitos, quando administrado ao mesmo, terapias de rnam do aumento invenção e/ou restaurar níveis insuficientes de expressão e/ou atividade da relaxina em indivíduos, terapias de rnam de a invenção ainda diminuir os níveis de metabolitos tóxicos associados com a atividade da relaxina deficiente em indivíduos.
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.</description><language>por</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190226&DB=EPODOC&CC=BR&NR=112018073683A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190226&DB=EPODOC&CC=BR&NR=112018073683A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KERRY BENENATO</creatorcontrib><creatorcontrib>ZHINAN XIA</creatorcontrib><creatorcontrib>VLADIMIR PRESNYAK</creatorcontrib><creatorcontrib>BARRY TICHO</creatorcontrib><creatorcontrib>ATHANASIOS DOUSIS</creatorcontrib><creatorcontrib>NADEGE BRIANCON-ERIS</creatorcontrib><creatorcontrib>SEYMOUR DE PICCIOTTO</creatorcontrib><creatorcontrib>STEPHEN HOGE</creatorcontrib><creatorcontrib>ELLALAHEWAGE SATHYAJITH KUMARASINGHE</creatorcontrib><creatorcontrib>IAIN MCFADYEN</creatorcontrib><title>polinucleotídeos codificadores de relaxina</title><description>a invenção refere-se a terapia de rnam para o tratamento de fibrose e/ou doença cardiovascular, os rnam para utilização na invenção, quando administrados in vivo, codificam a relaxina humana, as suas isoformas, fragmentos funcionais das mesmas, e proteínas de fusão compreendendo relaxina, mrnas da invenção são preferencialmente encapsulados em nanopartículas de lipídeos (lnps) para efetuar a entrega eficiente a células e/ou tecidos em sujeitos, quando administrado ao mesmo, terapias de rnam do aumento invenção e/ou restaurar níveis insuficientes de expressão e/ou atividade da relaxina em indivíduos, terapias de rnam de a invenção ainda diminuir os níveis de metabolitos tóxicos associados com a atividade da relaxina deficiente em indivíduos.
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAuyM_JzCtNzknNLzm8NiU1v1ghOT8lMy0zOTElvyi1WCElVaEoNSexIjMvkYeBNS0xpziVF0pzM6i6uYY4e-imFuTHpxYXJCan5qWWxDsFGRoaGRhaGJgbm1kYOxoZE6sOAEu5LEk</recordid><startdate>20190226</startdate><enddate>20190226</enddate><creator>KERRY BENENATO</creator><creator>ZHINAN XIA</creator><creator>VLADIMIR PRESNYAK</creator><creator>BARRY TICHO</creator><creator>ATHANASIOS DOUSIS</creator><creator>NADEGE BRIANCON-ERIS</creator><creator>SEYMOUR DE PICCIOTTO</creator><creator>STEPHEN HOGE</creator><creator>ELLALAHEWAGE SATHYAJITH KUMARASINGHE</creator><creator>IAIN MCFADYEN</creator><scope>EVB</scope></search><sort><creationdate>20190226</creationdate><title>polinucleotídeos codificadores de relaxina</title><author>KERRY BENENATO ; ZHINAN XIA ; VLADIMIR PRESNYAK ; BARRY TICHO ; ATHANASIOS DOUSIS ; NADEGE BRIANCON-ERIS ; SEYMOUR DE PICCIOTTO ; STEPHEN HOGE ; ELLALAHEWAGE SATHYAJITH KUMARASINGHE ; IAIN MCFADYEN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BR112018073683A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KERRY BENENATO</creatorcontrib><creatorcontrib>ZHINAN XIA</creatorcontrib><creatorcontrib>VLADIMIR PRESNYAK</creatorcontrib><creatorcontrib>BARRY TICHO</creatorcontrib><creatorcontrib>ATHANASIOS DOUSIS</creatorcontrib><creatorcontrib>NADEGE BRIANCON-ERIS</creatorcontrib><creatorcontrib>SEYMOUR DE PICCIOTTO</creatorcontrib><creatorcontrib>STEPHEN HOGE</creatorcontrib><creatorcontrib>ELLALAHEWAGE SATHYAJITH KUMARASINGHE</creatorcontrib><creatorcontrib>IAIN MCFADYEN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KERRY BENENATO</au><au>ZHINAN XIA</au><au>VLADIMIR PRESNYAK</au><au>BARRY TICHO</au><au>ATHANASIOS DOUSIS</au><au>NADEGE BRIANCON-ERIS</au><au>SEYMOUR DE PICCIOTTO</au><au>STEPHEN HOGE</au><au>ELLALAHEWAGE SATHYAJITH KUMARASINGHE</au><au>IAIN MCFADYEN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>polinucleotídeos codificadores de relaxina</title><date>2019-02-26</date><risdate>2019</risdate><abstract>a invenção refere-se a terapia de rnam para o tratamento de fibrose e/ou doença cardiovascular, os rnam para utilização na invenção, quando administrados in vivo, codificam a relaxina humana, as suas isoformas, fragmentos funcionais das mesmas, e proteínas de fusão compreendendo relaxina, mrnas da invenção são preferencialmente encapsulados em nanopartículas de lipídeos (lnps) para efetuar a entrega eficiente a células e/ou tecidos em sujeitos, quando administrado ao mesmo, terapias de rnam do aumento invenção e/ou restaurar níveis insuficientes de expressão e/ou atividade da relaxina em indivíduos, terapias de rnam de a invenção ainda diminuir os níveis de metabolitos tóxicos associados com a atividade da relaxina deficiente em indivíduos.
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | por |
| recordid | cdi_epo_espacenet_BR112018073683A2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | polinucleotídeos codificadores de relaxina |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A21%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KERRY%20BENENATO&rft.date=2019-02-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBR112018073683A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |